Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 193 results for transplantation

  1. Artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure (HTG459)

    Evidence-based recommendations on artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure. This involves replacing the 2 lower chambers of the heart with a mechanical device to improve circulation until heart transplantation.

  2. Tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium (HTG139)

    Evidence-based recommendations on tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium. This involves taking limbal stem cells from a living or deceased donor, growing them in the laboratory and transplanting them onto the patient’s affected eye(s).

  3. Implantation of a left ventricular assist device for destination therapy in people ineligible for heart transplantation (HTG369)

    Evidence-based recommendations on implantation of a left ventricular assist device for destination therapy in people ineligible for heart transplantation.

  4. Short-term circulatory support with left ventricular assist devices as a bridge to cardiac transplantation or recovery (HTG115)

    Evidence-based recommendations on short-term circulatory support with left ventricular assist devices (LVAD) as a bridge to heart transplantation or recovery. This involves inserting a mechanical device into the chest to help the heart pump blood around the body.

  5. Renal replacement therapy services for adults (QS72)

    This quality standard covers renal replacement therapy services for adults with kidney failure. It includes treatment options, such as dialysis and kidney transplant. It describes high-quality care in priority areas for improvement.

  6. Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)

    Evidence-based recommendations on bortezomib (Velcade) for treating multiple myeloma before chemotherapy and stem cell transplant in adults.

  7. Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)

    This guideline covers diagnosing and managing idiopathic pulmonary fibrosis in people aged 18 and over. It aims to improve the quality of life for people with idiopathic pulmonary fibrosis by helping healthcare professionals to diagnose the condition and provide effective symptom management.

  8. Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

    Evidence-based recommendations on machine perfusion systems and cold static storage of kidneys from deceased donors.

  9. Alcohol-use disorders: diagnosis and management of physical complications (CG100)

    This guideline covers care for adults and young people (aged 10 years and older) with physical health problems that are completely or partly caused by an alcohol-use disorder. It aims to improve the health of people with alcohol-use disorders by providing recommendations on managing acute alcohol withdrawal and treating alcohol-related conditions.

  10. Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)

    Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for treating multiple myeloma in adults.

  11. Extracorporeal whole liver perfusion for acute liver failure (HTG573)

    Evidence-based recommendations on extracorporeal whole liver perfusion for acute liver failure. This involves blood being diverted to a whole liver (perfusion) outside the body and returned to the patient.

  12. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.

  13. Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)

    Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults.

  14. Idelalisib for treating refractory follicular lymphoma (TA604)

    Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.